Cargando…

Levels of Soluble Endothelial Protein C Receptor Are Associated with CD4(+) Changes in Maraviroc-Treated HIV-Infected Patients

BACKGROUND: Inflammation is a key feature of HIV infection and is correlated with long-term negative cardiovascular outcomes. Therapy-induced increases in CD4(+) cell counts can control inflammation, as shown by decreases of coagulation and inflammation markers during efficacious therapy. Maraviroc,...

Descripción completa

Detalles Bibliográficos
Autores principales: Nozza, Silvia, Pogliaghi, Manuela, Chiappetta, Stefania, Spagnuolo, Vincenzo, Fontana, Gessica, Razzari, Cristina, Tambussi, Giuseppe, Faioni, Elena Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3371054/
https://www.ncbi.nlm.nih.gov/pubmed/22715361
http://dx.doi.org/10.1371/journal.pone.0037032
_version_ 1782235174291898368
author Nozza, Silvia
Pogliaghi, Manuela
Chiappetta, Stefania
Spagnuolo, Vincenzo
Fontana, Gessica
Razzari, Cristina
Tambussi, Giuseppe
Faioni, Elena Maria
author_facet Nozza, Silvia
Pogliaghi, Manuela
Chiappetta, Stefania
Spagnuolo, Vincenzo
Fontana, Gessica
Razzari, Cristina
Tambussi, Giuseppe
Faioni, Elena Maria
author_sort Nozza, Silvia
collection PubMed
description BACKGROUND: Inflammation is a key feature of HIV infection and is correlated with long-term negative cardiovascular outcomes. Therapy-induced increases in CD4(+) cell counts can control inflammation, as shown by decreases of coagulation and inflammation markers during efficacious therapy. Maraviroc, a CCR5-antagonist, has resulted in larger increases in CD4(+) counts both in naïve and experienced subjects compared to traditional antiretroviral therapy. OBJECTIVES AND METHODS: To examine if a member of the protein C anticoagulant and anti-inflammatory pathway, and marker of coagulation and inflammation, the soluble endothelial protein C receptor, is modified by infection and therapy-related variables in patients treated with Maraviroc. Endothelial protein C receptor, together with other established markers of inflammation and coagulation (CRP, IL-6, D-dimer and soluble thrombomodulin) was studied in 43 patients on traditional antiretroviral therapy and in 45 on Maraviroc during 48 weeks of follow-up. RESULTS: Soluble endothelial protein C receptor was the only marker that could discriminate at least partially between patients with a good response to Maraviroc and patients who did not respond with an adequate increase in CD4(+) cell counts (more than 500 cells/µL by week 48). CONCLUSIONS: Elevated levels of soluble endothelial protein C receptor, a sensitive marker of endothelial damage, indicated a low level of inflammation and coagulation activation in Maraviroc treated patients not picked up by other widely used markers. Persistent elevated levels of this marker at 48 weeks from beginning of treatment with Maraviroc were related to a poor increase in CD4(+) cells.
format Online
Article
Text
id pubmed-3371054
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-33710542012-06-19 Levels of Soluble Endothelial Protein C Receptor Are Associated with CD4(+) Changes in Maraviroc-Treated HIV-Infected Patients Nozza, Silvia Pogliaghi, Manuela Chiappetta, Stefania Spagnuolo, Vincenzo Fontana, Gessica Razzari, Cristina Tambussi, Giuseppe Faioni, Elena Maria PLoS One Research Article BACKGROUND: Inflammation is a key feature of HIV infection and is correlated with long-term negative cardiovascular outcomes. Therapy-induced increases in CD4(+) cell counts can control inflammation, as shown by decreases of coagulation and inflammation markers during efficacious therapy. Maraviroc, a CCR5-antagonist, has resulted in larger increases in CD4(+) counts both in naïve and experienced subjects compared to traditional antiretroviral therapy. OBJECTIVES AND METHODS: To examine if a member of the protein C anticoagulant and anti-inflammatory pathway, and marker of coagulation and inflammation, the soluble endothelial protein C receptor, is modified by infection and therapy-related variables in patients treated with Maraviroc. Endothelial protein C receptor, together with other established markers of inflammation and coagulation (CRP, IL-6, D-dimer and soluble thrombomodulin) was studied in 43 patients on traditional antiretroviral therapy and in 45 on Maraviroc during 48 weeks of follow-up. RESULTS: Soluble endothelial protein C receptor was the only marker that could discriminate at least partially between patients with a good response to Maraviroc and patients who did not respond with an adequate increase in CD4(+) cell counts (more than 500 cells/µL by week 48). CONCLUSIONS: Elevated levels of soluble endothelial protein C receptor, a sensitive marker of endothelial damage, indicated a low level of inflammation and coagulation activation in Maraviroc treated patients not picked up by other widely used markers. Persistent elevated levels of this marker at 48 weeks from beginning of treatment with Maraviroc were related to a poor increase in CD4(+) cells. Public Library of Science 2012-06-08 /pmc/articles/PMC3371054/ /pubmed/22715361 http://dx.doi.org/10.1371/journal.pone.0037032 Text en Nozza et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Nozza, Silvia
Pogliaghi, Manuela
Chiappetta, Stefania
Spagnuolo, Vincenzo
Fontana, Gessica
Razzari, Cristina
Tambussi, Giuseppe
Faioni, Elena Maria
Levels of Soluble Endothelial Protein C Receptor Are Associated with CD4(+) Changes in Maraviroc-Treated HIV-Infected Patients
title Levels of Soluble Endothelial Protein C Receptor Are Associated with CD4(+) Changes in Maraviroc-Treated HIV-Infected Patients
title_full Levels of Soluble Endothelial Protein C Receptor Are Associated with CD4(+) Changes in Maraviroc-Treated HIV-Infected Patients
title_fullStr Levels of Soluble Endothelial Protein C Receptor Are Associated with CD4(+) Changes in Maraviroc-Treated HIV-Infected Patients
title_full_unstemmed Levels of Soluble Endothelial Protein C Receptor Are Associated with CD4(+) Changes in Maraviroc-Treated HIV-Infected Patients
title_short Levels of Soluble Endothelial Protein C Receptor Are Associated with CD4(+) Changes in Maraviroc-Treated HIV-Infected Patients
title_sort levels of soluble endothelial protein c receptor are associated with cd4(+) changes in maraviroc-treated hiv-infected patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3371054/
https://www.ncbi.nlm.nih.gov/pubmed/22715361
http://dx.doi.org/10.1371/journal.pone.0037032
work_keys_str_mv AT nozzasilvia levelsofsolubleendothelialproteincreceptorareassociatedwithcd4changesinmaraviroctreatedhivinfectedpatients
AT pogliaghimanuela levelsofsolubleendothelialproteincreceptorareassociatedwithcd4changesinmaraviroctreatedhivinfectedpatients
AT chiappettastefania levelsofsolubleendothelialproteincreceptorareassociatedwithcd4changesinmaraviroctreatedhivinfectedpatients
AT spagnuolovincenzo levelsofsolubleendothelialproteincreceptorareassociatedwithcd4changesinmaraviroctreatedhivinfectedpatients
AT fontanagessica levelsofsolubleendothelialproteincreceptorareassociatedwithcd4changesinmaraviroctreatedhivinfectedpatients
AT razzaricristina levelsofsolubleendothelialproteincreceptorareassociatedwithcd4changesinmaraviroctreatedhivinfectedpatients
AT tambussigiuseppe levelsofsolubleendothelialproteincreceptorareassociatedwithcd4changesinmaraviroctreatedhivinfectedpatients
AT faionielenamaria levelsofsolubleendothelialproteincreceptorareassociatedwithcd4changesinmaraviroctreatedhivinfectedpatients